# Bruker Corp: Form 10-Q for the period ended Jun 30, 2022

- Company: [Bruker Corp](/companies/brkr.md) (CIK 1109354)
- Form: 10-Q
- Filed: 2022-08-05
- Accepted by EDGAR: Aug 5, 2022, 15:12 ET
- Period: 2022-06-30
- Accession: 0000950170-22-015090
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1109354/000095017022015090/brkr-20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1109354/000095017022015090/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $588.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $1.18bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $290.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $578.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-04-01 to 2022-06-30 | $298.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-01-01 to 2022-06-30 | $604.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $59.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $116.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-04-01 to 2022-06-30 | $152.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2022-01-01 to 2022-06-30 | $297.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | $73.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | $170.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $19.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $51.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | $49.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | $111.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.33 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.33 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 150 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 151 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | $33.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $36.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2022-01-01 to 2022-06-30 | $15.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2022-01-01 to 2022-06-30 | $165.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-06-30 | $723.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $2.09bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $3.38bn | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $818.4m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2022-06-30 | $1.17bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2022-06-30 | $970.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 49,793 characters.

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2021.

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q, which express that we “believe,” “anticipate,” “plan,” “expect,” “seek,” “may,” “will,” “intend,” “estimate,” “should” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the impact of COVID-19 on our business operations, the impact of supply chain challenges, expectations regarding the global economy, inflation, the potential for recession and geopolitical tensions, our intentions regarding our intellectual property, the impact of government contracts and government regulation, our working capital requirements and sufficiency of cash, our competition, the seasonality of our business, the sufficiency of our facilities, our employee relations, the impact of legal or intellectual property proceedings, the impact of changes to tax and accounting rules and changes in law, our anticipated tax rate, our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures, the impact of foreign currency exchange rates and changes in commodity prices, the impact of our restructuring initiatives, our expectations regarding backlog and revenue and other risk factors discussed herein and from time to time in our other filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2021 and subsequent filings. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

### Non-GAAP Measures

Although our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. We rely internally on certain measures that are not calculated according to GAAP. These measures are organic revenue, free cash flow, non-GAAP gross profit margin and non-GAAP operating margin. Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We define the term organic revenue as GAAP revenue excluding the effect of foreign currency translation changes and the effect of acquisitions and divestitures. We define the term non-GAAP gross profit margin as GAAP gross profit margin with certain non-GAAP measures excluded and non-GAAP operating margin as GAAP operating margin with certain non-GAAP measures excluded. These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other non-operational costs and we believe these are useful measures to evaluate our continuing business.

We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends and repayment of debt. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.

### OVERVIEW

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, Asia and North America and we have sales offices located throughout the world. Bruker is organized into three reportable segments: the BSI Life Science segment (comprised of the Bruker BioSpin Group and the Bruker CALID Group), the BSI Nano segment and the Bruker Energy & Supercon Technologies (BEST) segment.

Revenue for the three months ended June 30, 2022 increased by $17.6 million, or 3.1%, to $588.4 million, compared to $570.8 million for the comparable period in 2021. Included in revenue was a decrease of approximately $41.8 million from unfavorable foreign exchange rate movements, offset by an increase of $9.3 million from acquisitions. Excluding the unfavorable effects of foreign exchange rate movements and our recent acquisitions, our organic revenue, a non-GAAP measure, increased $50.1 million. Revenue increases were driven by strong demand for our differentiated high-value scientific instruments and life science solutions compared to the same period in 2021.

Revenue for the six months ended June 30, 2022 increased by $57.9 million, or 5.1% to $1,183.4 million, compared to $1,125.5 million for the comparable period in 2021. Included in revenue was a decrease of approximately $65.5 million from unfavorable foreign exchange rate movements, offset by an increase of $15.1 million from acquisitions. Excluding the unfavorable effects of foreign exchange rate movements and our recent acquisitions, our organic revenue, a non-GAAP measure, increased $108.3 million. Revenue increases were driven by strong demand for our differentiated high-value scientific instruments and life science solutions compared to the same period in 2021.

Our gross profit margin increased to 50.7% during the three months ended June 30, 2022, as compared to 49.2% in the same period in 2021, the result of higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges compared to 2021.

Our gross profit margin increased to 51.1% during the six months ended June 30, 2022, as compared to 49.7% in the same period in 2021, the result of higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges compared to 2021.

Our income tax provision in the three months ended June 30, 2022 and 2021 was $19.9 million and $21.3 million, respectively, representing effective tax rates of 28.6% and 26.6%, respectively. Our income tax provision in the six months ended June 30, 2022 and 2021 was $51.8 million and $48.8 million, respectively, representing effective tax rates of 31.7% and 29.5%, respectively. The increase in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective in 2022 limiting the deductibility of research and development expenses and the benefit relating to foreign tax credits and the resolution of the United States-Germany Mutual Agreement Procedures tax audit.

Diluted earnings per share for the three months ended June 30, 2022 was $0.33, a decrease of $0.05 compared to $0.38 per share in the same period in 2021. Diluted earnings per share for the six months ended June 30, 2022 was $0.74, a decrease of $0.01 compared to $0.75 per share in the same period in 2021. The decrease in diluted earnings per share in both the three months and six months ended June 30, 2022 was primarily driven by lower net income and from acquisition related hybrid instrument liability adjustments recognized during the periods.

The following table presents a reconciliation from net cash provided by operating activities, which is the most directly comparable GAAP operating financial measure, to free cash flow as used by management (in millions):

|  | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $33.4 | $119.9 |
| Less: purchases of property, plant and equipment | (36.9) | (47.3) |
| Free cash flow | $(3.5) | $72.6 |

27

The following table presents reconciliations from gross profit and gross profit margin, which are the most directly comparable GAAP operating performance measures, to non-GAAP gross profit and non-GAAP gross profit margin as used by management (in millions):

|  | Three Months Ended June 30, 2022 |  | 2021 |  | Six Months Ended June 30, 2022 |  | 2021 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $298.2 | 50.7% | $280.6 | 49.2% | $604.5 | 51.1% | $559.3 | 49.7% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| Restructuring costs | 1.3 | 0.2% | 0.3 | — | 1.4 | 0.1% | 1.4 | 0.1% |
| Acquisition-related costs | — | — | — | — | 0.2 | — | — | — |
| Purchased intangible amortization | 4.5 | 0.8% | 5.2 | 0.9% | 9.0 | 0.8% | 9.7 | 0.8% |
| Other costs | 0.7 | 0.1% | (0.5) | -0.1% | 2.9 | 0.2% | (0.5) | — |
| Non-GAAP gross profit | $304.7 | 51.8% | $285.6 | 50.0% | $618.0 | 52.2% | $569.9 | 50.6% |

Our non-GAAP gross profit margin was 51.8% and 50.0% in the three months ended June 30, 2022 and 2021, respectively. Our non-GAAP gross profit margin was 52.2% and 50.6% in the six months ended June 30, 2022 and 2021, respectively. The increases in our non-GAAP gross profit margins in both the three months and six months ended June 30, 2022 were driven by higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges compared to 2021.

The following table presents reconciliations from operating income and operating margin, which are the most directly comparable GAAP operating performance measures, to non-GAAP operating income and non-GAAP operating margin as used by management (in millions):

|  | Three Months Ended June 30, 2022 |  | 2021 |  | Six Months Ended June 30, 2022 |  | 2021 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $73.9 | 12.6% | $85.6 | 15.0% | $170.4 | 14.4% | $174.7 | 15.5% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| Restructuring costs | 3.8 | 0.6% | 1.7 | 0.3% | 4.2 | 0.4% | 4.1 | 0.4% |
| Acquisition-related costs | 8.3 | 1.4% | 2.3 | 0.4% | 13.6 | 1.1% | 3.2 | 0.3% |
| Purchased intangible amortization | 9.3 | 1.6% | 9.0 | 1.6% | 18.6 | 1.6% | 18.0 | 1.6% |
| Other costs | 2.4 | 0.4% | 0.2 | — | 6.7 | 0.5% | 1.0 | 0.1% |
| Non-GAAP operating income | $97.7 | 16.6% | $98.8 | 17.3% | $213.5 | 18.0% | $201.0 | 17.9% |

Our non-GAAP operating margin was 16.6% and 17.3% in the three months ended June 30, 2022 and 2021, respectively. Our non-GAAP operating margin was 18.0% and 17.9% in the six months ended June 30, 2022 and 2021, respectively. Our non-GAAP operating margin decreased in 2022 due to increased investments in sales and marketing and in our research and development capabilities, as compared to 2021.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

- the impact of the COVID-19 global pandemic, inflation, the threat of recession and geopolitical tensions on our customers, supply chain or manufacturing capabilities;
- the impact of certain weather-related disruptions;
- the timing of governmental stimulus programs and academic research budgets;
- the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;
- foreign currency exchange rates;
- the time it takes for us to receive critical materials to manufacture our products;
- general economic conditions, including the impact of COVID-19 or other factors on the global economy;
- the time it takes to satisfy local customs requirements and other export/import requirements;
- the time it takes for customers to construct or prepare their facilities for our products; and
- the time required to obtain governmental licenses.

Several of these factors have in the past affected and continue to affect the amount and timing of revenue recognized on sales of our products and receipt of related payments and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance. The COVID-19 pandemic continues to present a challenging operating environment. Throughout the COVID-19 pandemic, we have been focused on and continue to focus on three key priorities: the health and safety of our employees, customers and partners; maintaining business continuity and service levels for our customers; and delivering enabling research and diagnostic products to help fight the pandemic, and to support other essential priorities of our society.

### Health and safety of our valued employees, customers and partners

In response to the COVID-19 pandemic, we implemented strict social distancing, enhanced cleaning protocols and other preventative measures, in our major facilities to ensure the health and safety of our valued employees, customers and partners. While many of our office colleagues worked remotely at the height of the pandemic and through subsequent surges, we placed enhanced focus on the safety of our service organization and factory employees for whom work from home was not feasible. Where customer sites were accessible and open, our field service organizations operated under social distancing protocols with proper face coverings to ensure the safety of customer sites, when our employees needed to be on site. Consistent with local government and health organization guidelines, many of our facilities have started a gradual return to the office for employees who have been working remotely. As we continue to monitor developments and make appropriate adjustments, as needed, employee and visitor health and safety will remain our paramount concern.

### Maintaining business continuity and service levels to our customers

Ensuring our ability to supply our enabling technologies and solutions and maintaining high service levels for our customers is another top priority for Bruker. In late March and during parts of April 2020, several of our manufacturing sites underwent temporary controlled shutdowns or were operating at reduced capacity to implement new safety protocols, comply with local rules, and manage cost and inventory levels. These sites thereafter ramped back up with expanding capacity and productivity levels. However, with any resurgence of the virus or the emergence of additional variants and subvariants, particularly those that are resistant to existing vaccines, we may again need to consider temporary controlled shutdowns or reduced capacity measures. In addition, we are continuing capital investments in production facilities for efficiencies and expansion. We continue to encounter supply chain risks associated with the pandemic, the global economy, including inflation and the threat of recession and geopolitical tensions, and the worldwide shortage of semiconductor chips, components and raw materials, such as copper.

### Delivering enabling research and diagnostic products to help fight the pandemic and to support other essential priorities of our society

Bruker is providing critical technologies and solutions to help combat the COVID-19 pandemic, most notably our Microbiology and infectious disease diagnostics portfolio and our nuclear magnetic resonance and mass spectrometry systems which are used in critical disease, therapeutic and vaccine research.

The COVID-19 global pandemic has driven volatility and uncertainty in global markets and has in the past affected our operations significantly. We continue to work to manage the impact of COVID-19 on our operations; however, the full extent to which any resurgence of the virus, the emergence of any new variants and subvariants, or the availability and effectiveness of COVID-19 vaccines will impact our business, directly or indirectly, cannot accurately be predicted at this time. We continue to monitor the impact of COVID-19 on our business and our supply chain and respond accordingly.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to: revenue recognition; stock-based compensation expense; restructuring and other related charges; income taxes, including the recoverability of deferred tax assets; allowances for doubtful accounts; inventory reductions for excess and obsolete inventories; estimated fair values of long-lived assets used to measure the recoverability of long-lived assets; intangible assets and goodwill; expected future cash flows used to measure the recoverability of intangible assets and long-lived assets; warranty costs; derivative financial instruments; and contingent liabilities. We base our estimates and judgments on our historical experience, current market and economic conditions, industry trends, and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

We believe the following critical accounting policies and estimates to be both those most important to the portrayal of our financial position and results of operations and those that require the most estimation and subjective judgment:

- Revenue recognition;
- Income taxes;
- Inventories;
- Goodwill, other intangible assets and other long-lived assets; and
- Business combinations.

For a further discussion of our critical accounting policies, please refer to our Annual Report on Form 10-K for the year ended December 31, 2021.

### RESULTS OF OPERATIONS

#### Three Months Ended June 30, 2022 compared to the Three Months Ended June 30, 2021

### Consolidated Results

The following table presents our results (in millions):

|  | Three Months Ended June 30, 2022 | 2021 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $485.8 | $474.3 | $11.5 | 2.4% |
| Service revenue | 100.9 | 94.7 | 6.2 | 6.5% |
| Other revenue | 1.7 | 1.8 | (0.1) | (5.6)% |
| Total revenue | 588.4 | 570.8 | 17.6 | 3.1% |
| Cost of product revenue | 230.1 | 236.0 | (5.9) | (2.5)% |
| Cost of service revenue | 60.1 | 54.1 | 6.0 | 11.1% |
| Cost of other revenue | — | 0.1 | (0.1) | (100.0)% |
| Total cost of revenue | 290.2 | 290.2 | — | — |
| Gross profit | 298.2 | 280.6 | 17.6 | 6.3% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 152.2 | 134.8 | 17.4 | 12.9% |
| Research and development | 59.6 | 55.8 | 3.8 | 6.8% |
| Other charges, net | 12.5 | 4.4 | 8.1 | 184.1% |
| Total operating expenses | 224.3 | 195.0 | 29.3 | 15.0% |
| Operating income | 73.9 | 85.6 | (11.7) | (13.7)% |
| Interest and other income (expense), net | (4.3) | (5.6) | 1.3 | (23.2)% |
| Income before income taxes and noncontrolling interests in consolidated subsidiaries | 69.6 | 80.0 | (10.4) | (13.0)% |
| Income tax provision | 19.9 | 21.3 | (1.4) | (6.6)% |
| Consolidated net income | 49.7 | 58.7 | (9.0) | (15.3)% |
| Net income attributable to noncontrolling interests in consolidated subsidiaries | 0.2 | 1.1 | (0.9) | (81.8)% |
| Net income attributable to Bruker Corporation | $49.5 | $57.6 | $(8.1) | (14.1)% |

### Revenue

Revenue increases were driven by strong demand for our differentiated instruments and solutions offset by the negative impact of foreign currency translation. The BioSpin Group revenue for the three months ended June 30, 2022 was $159.8 million, an increase of 7.6% compared to the same period in 2021. The increase related primarily to the revenue recognition of an ultra-high-field NMR system as well as from services and support. The CALID Group revenue for the three months ended June 30, 2022 was $190.3 million, a slight decrease of 1.6% compared to the same period in 2021. The decrease in revenues was a direct result of supply chain constraints. BSI Nano revenue for the three months ended June 30, 2022 was $182.2 million, an increase of 3.9% compared to the same period in 2021. The increase in BSI Nano revenue was driven by strong demand in its industrial and semiconductor metrology markets. The BEST revenue for the three months ended June 30, 2022 was $59.2 million, an increase of 4.6% compared to the same period in 2021, driven by strong superconductor demand from our magnetic resonance imaging original equipment manufacturer customers.

Geographically in the second quarter 2022, our North American revenue grew 10.4%, Asia Pacific increased by 14.9%, while European revenue declined by 8.3% compared to the same period in 2021.

### Gross Profit

The increase in gross profit in the three months ended June 30, 2022, as compared to the same period in 2021, was a result of higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges and inflationary margin challenges compared to 2021.

### Selling, General and Administrative

Our selling, general and administrative expenses for the three months ended June 30, 2022 increased to 25.9% of total revenue, from 23.6% of total revenue for the comparable period in 2021. The increase as a percentage of revenue was a result of certain sales and marketing investments and driven by higher freight, logistics and commission costs.

### Research and Development

Our research and development expenses for the three months ended June 30, 2022 increased to 10.1% of total revenue from 9.8% of total revenue for the comparable period in 2021. The increase as a percentage of revenue is a result of our increased investment in research and development capabilities period over period in addition to the impact of supply chain constraints on total revenues in the period.

### Other Charges, Net

Other charges, net for the three months ended June 30, 2022 consisted of $8.3 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.5 million of restructuring costs, $1.5 million of costs associated with our global information technology (IT) transformation activities, and $0.2 million of other charges. The IT transformation initiative is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.

Other charges, net for the three months ended June 30, 2021 consisted of $2.3 million of acquisition-related charges to acquisitions completed in 2021 and 2020, $1.4 million of restructuring costs, $0.8 million of costs associated with our global IT transformation activities offset by a $0.1 million adjustment of other charges.

### Operating Income

The decrease in operating income was due to higher gross profit resulting from differentiated instruments and solutions offset by certain sales and marketing investments and investments research and development capabilities.

### Interest and Other Income (Expense), Net

The decline in interest and other income (expense), net in the three months ended June 30, 2022, as compared to the same period in 2021 was primarily due to lower foreign currency exchange losses driven by strengthening of the U.S. dollars against other currencies.

### Income Tax Provision

The 2022 and 2021 effective tax rates were estimated using projected annual pre-tax income on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances and the effect of jurisdictional differences in statutory tax rates were also considered in the calculation.

The effective tax rates for the three months ended June 30, 2022 and 2021 were 28.6% and 26.6%, respectively. The increase in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective 2022 limiting the deductibility of research and development expenses and the benefit relating to foreign tax credits and the resolution of the United States-Germany Mutual Agreement Procedures tax audit.

### Net Income Attributable to Noncontrolling Interests

The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.

### Reportable Segment Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment (in millions):

|  | Three Months Ended June 30, 2022 | 2021 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| BSI Life Science | $350.1 | $341.8 | $8.3 | 2.4% |
| BSI Nano | 182.2 | 175.3 | 6.9 | 3.9% |
| BEST | 59.2 | 56.6 | 2.6 | 4.6% |
| Eliminations (a) | (3.1) | (2.9) | (0.2) |  |
| Total revenue | $588.4 | $570.8 | $17.6 | 3.1% |

(a) Represents product and service revenue between reportable segments.

For financial reporting purposes, we aggregate the Bruker BioSpin Group and Bruker CALID Group as the BSI Life Science segment. This aggregation reflects the similar economic characteristics, production processes, customer services provided, types and classes of customers, methods of distribution and regulatory environments.

The increase in revenue for the BSI Life Science segment in the three months ended June 30, 2022 was due to strong demand, business and end market recovery, and was led by recognition of an ultra-high-field NMR system as well as from services and support offset by supply chain constraints. The increase in revenue for the BSI Nano segment was driven by strong demand in industrial research and semiconductor customers. The increase in revenue for the BEST segment resulted from strong superconductor demand by our magnetic resonance imaging original equipment manufacturer customers.

### Operating Income

The following table presents operating income and operating margins on revenue by reportable segment (in millions):

|  | Three Months Ended June 30, 2022 Operating Income (Loss) | Percentage of Segment Revenue | 2021 Operating Income (Loss) | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI Life Science | $70.2 | 20.1% | $73.6 | 21.5% |
| BSI Nano | 14.6 | 8.0% | 21.0 | 12.0% |
| BEST | 6.6 | 11.1% | 6.8 | 12.0% |
| Corporate, eliminations and other (a) | (17.5) |  | (15.8) |  |
| Total operating income | $73.9 | 12.6% | $85.6 | 15.0% |

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

The operating margin decreases in the BSI Life Science and BSI Nano segments was primarily due to higher gross margin resulting from higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements offset by planned sales and marketing investments, supply chain and logistics challenges and inflationary margin challenges in 2022, as compared to 2021, and investments in research and development capabilities. The operating margin decrease in the BEST segment resulted from inflationary margin challenges in 2022, as compared to 2021.

### Consolidated Results

#### Six Months Ended June 30, 2022 compared to the Six Months Ended June 30, 2021

The following table presents our results (in millions):

|  | Six Months Ended June 30, 2022 | 2021 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $976.2 | $932.9 | $43.3 | 4.6% |
| Service revenue | 204.1 | 188.8 | 15.3 | 8.1% |
| Other revenue | 3.1 | 3.8 | (0.7) | (18.4)% |
| Total revenue | 1,183.4 | 1,125.5 | 57.9 | 5.1% |
| Cost of product revenue | 459.1 | 456.9 | 2.2 | 0.5% |
| Cost of service revenue | 119.7 | 108.8 | 10.9 | 10.0% |
| Cost of other revenue | 0.1 | 0.5 | (0.4) | (80.0)% |
| Total cost of revenue | 578.9 | 566.2 | 12.7 | 2.2% |
| Gross profit | 604.5 | 559.3 | 45.2 | 8.1% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 297.9 | 266.6 | 31.3 | 11.7% |
| Research and development | 116.2 | 110.6 | 5.6 | 5.1% |
| Other charges, net | 20.0 | 7.4 | 12.6 | 170.3% |
| Total operating expenses | 434.1 | 384.6 | 49.5 | 12.9% |
| Operating income | 170.4 | 174.7 | (4.3) | (2.5)% |
| Interest and other income (expense), net | (6.8) | (9.4) | 2.6 | (27.7)% |
| Income before income taxes and noncontrolling interests in consolidated subsidiaries | 163.6 | 165.3 | (1.7) | (1.0)% |
| Income tax provision | 51.8 | 48.8 | 3.0 | 6.1% |
| Consolidated net income | 111.8 | 116.5 | (4.7) | (4.0)% |
| Net income attributable to noncontrolling interests in consolidated subsidiaries | 0.7 | 2.2 | (1.5) | (68.2)% |
| Net income attributable to Bruker Corporation | $111.1 | $114.3 | $(3.2) | (2.8)% |

### Revenue

Revenue increases were driven by strong demand for our differentiated instruments and solutions offset by the negative impact of foreign currency translation. The BioSpin Group revenue for the six months ended June 30, 2022 was $317.6 million, an increase of 3.2% compared to the same period in 2021. The increase was driven by strong growth in the applied markets. The CALID Group revenue for the six months ended June 30, 2022 was $393.5 million, a slight increase of 2.0% compared to the same period in 2021. The increase in revenues was a direct result of strong growth in life science mass spectrometry and microbiology aftermarket business, but also impacted by supply chain constraints. BSI Nano revenue for the six months ended June 30, 2022 was $360.7 million, an increase of 9.4% compared to the same period in 2021. The increase in BSI Nano revenue was driven by strong demand in its industrial and semiconductor metrology markets. The BEST revenue for the six months ended June 30, 2022 was $118.9 million, an increase of 9.1% compared to the same period in 2021, driven by strong superconductor demand from major medical magnetic resonance imaging manufacturers.

Geographically in the six months ended June 30, 2022, our North American revenue grew 19.8%, Asia Pacific increased by 9.3%, while European revenue declined by 8.3% compared to the same period in 2021.

### Gross Profit

The increase in gross profit in the six months ended June 30, 2022, as compared to the same period in 2021, was a result of higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges and inflationary margin challenges compared to 2021.

### Selling, General and Administrative

Our selling, general and administrative expenses for the six months ended June 30, 2022 increased to 25.2% of total revenue, from 23.7% of total revenue for the comparable period in 2021. The increase as a percentage of revenue was a result of investments in our commercial infrastructure and driven by higher freight, logistics and commission costs.

### Research and Development

Our research and development expenses as a percentage of total revenue for the six months ended June 30, 2022 was 9.8% equal to the same period in 2021. The consistent percentage relates to higher overall revenues in addition to our increased investment in research and development capabilities period over period.

### Other Charges, Net

Other charges, net for the six months ended June 30, 2022 consisted of $13.4 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.8 million of restructuring costs, $2.5 million of costs associated with our global information technology (IT) transformation activities, $0.8 million of other charges, and $0.5 million related to suspension of operations in Russia.

Other charges, net for the six months ended June 30, 2021 consisted of $3.2 million of acquisition-related charges to acquisitions completed in 2021 and 2020, $2.7 million of restructuring costs and $1.5 million of costs associated with our global IT transformation activities.

### Operating Income

The decrease in operating income was due to higher gross profit resulting from higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements offset by planned sales and marketing investments, supply chain and logistics challenges and inflationary margin challenges in 2022, as compared to 2021, and investments in research and development capabilities.

### Interest and Other Income (Expense), Net

The decline in interest and other income (expense), net in the six months ended June 30, 2022, as compared to the same period in 2021 was primarily due to increased interest expense on our 2021 Note Purchase Agreement offset by lower foreign currency exchange losses driven by strengthening of the U.S. dollars against other currencies as well as unrealized gains from investments at cost.

### Income Tax Provision

The 2022 and 2021 effective tax rates were estimated using projected annual pre-tax income on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances and the effect of jurisdictional differences in statutory tax rates were also considered in the calculation.

The effective tax rates for the six months ended June 30, 2022 and 2021 were 31.7% and 29.5% respectively. The increase in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective in 2022 limiting the deductibility of research and development expenses and the benefit relating to foreign tax credits and the resolution of the United States-Germany Mutual Agreement Procedures tax audit.

### Net Income Attributable to Noncontrolling Interests

The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.

### Reportable Segment Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment (in millions):

|  | Six Months Ended June 30, 2022 | 2021 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| BSI Life Science | $711.1 | $693.6 | $17.5 | 2.5% |
| BSI Nano | 360.7 | 329.7 | 31.0 | 9.4% |
| BEST | 118.9 | 109.0 | 9.9 | 9.1% |
| Eliminations (a) | (7.3) | (6.8) | (0.5) |  |
| Total revenue | $1,183.4 | $1,125.5 | $57.9 | 5.1% |

(a) Represents product and service revenue between reportable segments.

The increase in revenue for the BSI Life Science segment in the six months ended June 30, 2022 was due to strong demand, business and end market recovery, and was led by recognition of an ultra-high-field NMR system as well as strong growth in the applied markets offset by supply chain constraints. The increase in revenue for the BSI Nano segment was driven by strong demand in industrial research and semiconductor customers. The increase in revenue for the BEST segment resulted from strong superconductor demand by our magnetic resonance imaging original equipment manufacturer customers.

### Operating Income

The following table presents operating income and operating margins on revenue by reportable segment (in millions):

|  | Six Months Ended June 30, 2022 Operating Income (Loss) | Percentage of Segment Revenue | 2021 Operating Income (Loss) | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI Life Science | $156.1 | 22.0% | $162.5 | 23.4% |
| BSI Nano | 36.9 | 10.2% | 33.3 | 10.1% |
| BEST | 13.2 | 11.1% | 10.9 | 10.0% |
| Corporate, eliminations and other (a) | (35.8) |  | (32.0) |  |
| Total operating income | $170.4 | 14.4% | $174.7 | 15.5% |

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

The operating margin increases in the BSI Life Science and BSI Nano segments was primarily due to higher gross margin resulting from differentiated products and operating leverage, partially offset by planned commercial investments. The operating margin increase in the BEST segment resulted from higher revenue and favorable mix.

### LIQUIDITY AND CAPITAL RESOURCES

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, purchases of our common stock or the payment of dividends in the future. Historically, we have financed our growth and liquidity needs through cash flow generation from operations and a combination of debt financings and issuances of common stock. In the future, there are no assurances that we will continue to generate cash flow from operations or that additional financing alternatives will be available to us, if required, or if available, will be obtained on terms favorable to us.

Cash, cash equivalents and short-term investments at June 30, 2022 and December 31, 2021 totaled $723.0 million and $1,168.2 million, respectively, of which $561.3 million and $646.9 million, respectively, related to cash, cash equivalents and short-term investments held outside of the U.S. in our foreign subsidiaries, most significantly in the Netherlands, Switzerland and Hong Kong.

The following table presents our cash flows from operating activities, investing activities and financing activities for the periods presented (in millions):

|  | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $33.4 | $119.9 |
| Net cash used in investing activities | (44.7) | (95.4) |
| Net cash used in financing activities | (297.2) | (83.0) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (36.9) | (15.3) |
| Net change in cash, cash equivalents and restricted cash | $(345.4) | $(73.8) |

Cash provided by operating activities during the six months ended June 30, 2022 resulted primarily from consolidated net income adjusted for non-cash items of $168.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $135.1 million. The decrease was primarily due to strategic inventory management to handle supply chain challenges, timing of tax payments partially offset by customer advances received during the period related to new orders and deferral of revenue due to supply chain challenges. Cash provided by operating activities during the six months ended June 30, 2021 resulted from consolidated net income adjusted for non-cash items of $185.1 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $65.2 million. The primary increase is a result of increased net income driven by the increase in revenue, gross profit and operating profit as a result of the rebounding in our business and end markets. The decrease in operating assets and liabilities, net of acquisitions and divestitures for the six months ended June 30, 2021 was primarily due to improved inventory management, higher payables and accrued liabilities partially offset by a decrease in cash received from customers due to timing of payments as compared to the same period in the prior year.

Cash used in investing activities during the six months ended June 30, 2022 resulted primarily from acquisitions of $85.4 million, purchases of property, plant and equipment of $36.9 million, and strategic investments of $38.1 million, offset by maturity of short-term investments of $100.0 million and $13.8 million of net proceeds from sales of property, plant and equipment. Cash used in investing activities during the six months ended June 30, 2021 resulted mainly from purchases of property, plant and equipment of $47.3 million, purchases of short-term investments of $48.0 million and acquisitions of $4.0 million.

Net cash used in financing activities during the six months ended June 30, 2022 was primarily from cash paid for purchases of common stock under our repurchase program of $165.9 million, repayment of our 2012 Note Purchase Agreement of $105.0 million and $15.0 million for the payment of dividends. Net cash used in financing activities during the six months ended June 30, 2021 was primarily from cash paid for purchases of common stock under our repurchase program of $71.1 million and $12.1 million for the payment of dividends.

### Share Repurchase Program

In May 2019, our Board of Directors approved our share repurchase program (the “2019 Repurchase Program”) under which repurchases of common stock in the amount of up to $300.0 million were authorized to occur from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. During the three months ended June 30, 2021, we purchased 24,873 shares at an aggregate cost of $1.7 million under the 2019 Repurchase Program. During the six months ended June 30, 2021, we purchased a total of 555,602 shares at an aggregate cost of $34.5 million under the 2019 Repurchase Program. We completed the 2019 Repurchase Program in April 2021, after reaching the maximum cumulative spend.

In May 2021, our Board of Directors approved a share repurchase program (the “2021 Repurchase Program”) authorizing the purchase of up to $500.0 million of our common stock over a two-year period from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. During the three months ended June 30, 2022, we purchased 983,741 shares at an aggregate cost of $60.3 million under the 2021 Repurchase Program. During the six months ended June 30, 2022, we purchased a total of 2,586,796 shares at an aggregate cost of $165.9 million under the 2021 Repurchase Program. We purchased a total of 530,703 shares with an aggregate cost of $36.6 million in the three and six months ended June 30, 2021 under the 2021 Repurchase Program. At June 30, 2022, $215.3 million remained for future purchase under the 2021 Repurchase Program. We intend to fund any additional repurchases from cash on hand, future cash flows from operations and available borrowings under our revolving credit facility. The purchased shares are reflected within Treasury stock in the accompanying unaudited condensed consolidated balance sheets.

### Credit Facilities

On December 7, 2021, we entered into a note purchase agreement to issue and sell CHF 300 million aggregate principal amount of 0.88% series A senior notes and EUR 150 million aggregate principal amount of 1.03% series B senior notes due December 8, 2031. We designated our CHF 300 million series A senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. We designated our EUR 150 million series B senior notes as a hedge in our net investment in our EUR denominated net assets. Proceeds of the notes will be used for general corporate purposes.

On December 11, 2019, we entered into (1) a new revolving credit agreement to establish a new revolving credit facility in the aggregate principal amount of $600 million; (2) a term loan agreement to establish a new term loan facility in the aggregate principal amount of $300 million; and (3) a note purchase agreement to issue and sell CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. Floating interest rates under the term loan were simultaneously fixed through cross-currency and interest rate swap agreements into Euro ($150 million) and Swiss Franc ($150 million) rates carrying average effective interest rates of 0.94% and hedge our net investment in our Euro and Swiss Franc denominated net assets.

In addition, we designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Proceeds from this financing were used to repay the outstanding borrowings under our prior 2015 revolving credit facility and we intend to use the remaining proceeds for general corporate purposes and to support corporate strategic objectives. During December 2019, we entered into U.S. Dollar to Euro cross-currency swaps on our existing 2012 private placement notes of $105 million 4.31% Series 2012A Senior Notes, Tranche C, repaid in January 2022, and the existing $100 million of 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024, resulting in an average effective interest rate of 2.25% on these instruments. The cross-currency swaps hedge our net investment in our Euro denominated net assets.

As of June 30, 2022, we have several cross-currency and interest rate swap agreements with a notional value of $148.9 million of U.S. to Swiss Franc and a notional value of $248.9 million of U.S. to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. As a result of entering into these agreements, the Company lowered net interest expense by $1.6 million and $1.3 million during the three months ended June 30, 2022 and 2021, respectively and $2.7 million during each of the six months ended June 30, 2022 and 2021, respectively. We anticipate these swap agreements will lower net interest expense in future years.

We had the following debt outstanding (in millions):

|  | June 30, 2022 | December 31, 2021 |
| --- | ---: | ---: |
| EUR notes (in U.S. dollars) under the 2021 Note Purchase Agreement | $157.3 | $170.7 |
| CHF notes (in U.S. dollars) under the 2021 Note Purchase Agreement | 314.5 | 329.2 |
| CHF notes (in U.S. dollars) under the 2019 Note Purchase Agreement | 311.4 | 325.9 |
| U.S. Dollar notes under the 2019 Term Loan | 297.8 | 299.2 |
| U.S. Dollar notes under the 2012 Note Purchase Agreement | 100.0 | 205.0 |
| Unamortized debt issuance costs | (1.8) | (2.0) |
| Other loans | 1.8 | 1.9 |
| Total notes and loans outstanding | 1,181.0 | 1,329.9 |
| Finance lease obligations | 4.0 | 4.3 |
| Total debt | 1,185.0 | 1,334.2 |
| Current portion of long-term debt | (14.0) | (112.4) |
| Total long-term debt, less current portion | $1,171.0 | $1,221.8 |

As of June 30, 2022, we had no off-balance sheet arrangements.

The following is a summary of the maximum commitments and the net amounts available to us under the 2019 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at June 30, 2022 (in millions):

|  | Weighted Average Interest Rate | Total Amount Committed by Lenders | Outstanding Borrowings | Outstanding Letters of Credit | Total Amount Available |
| --- | ---: | ---: | ---: | ---: | ---: |
| 2019 Credit Agreement | 1.3% | $600.0 | $— | $0.1 | $599.9 |
| Bank guarantees and working capital line | varies | 108.7 | — | 108.7 | — |
| Total revolving lines of credit |  | $708.7 | $— | $108.8 | $599.9 |

38

As of June 30, 2022, we were compliant with the financial covenants of these debt agreements.

### RECENT ACCOUNTING PRONOUNCEMENTS

Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. See Note 2 in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for recently adopted and issued accounting standards.

## Market risk

As filed, 10,576 characters.

We are potentially exposed to market risks associated with changes in foreign currency translation rates, interest rates and commodity prices. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign currency translation and interest rate risk include market valuations and sensitivity analysis.

### Foreign Currency Risk

We generate a substantial portion of our revenues in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which exposes our operations to the risk of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, reducing our transaction risk exposure. However, for foreign currency denominated sales in certain regions, such as Japan, where we do not incur significant costs denominated in Japanese Yen, we are more exposed to the impact of foreign currency fluctuations.

For sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we would have received before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency. For example, if the U.S. dollar strengthened against the Japanese Yen, our Japanese-based competitors would have a greater pricing advantage over us.

Changes in foreign currency translation rates decreased our revenue by 7.3% and increased our revenue by 6.8% for the three months ended June 30, 2022 and 2021, respectively. Changes in foreign currency translation rates decreased our revenue by 5.8% and increased our revenue by 6.5% for the six months ended June 30, 2022 and 2021, respectively.

Assets and liabilities of our foreign subsidiaries, where the functional currency is the local currency, are translated into U.S. dollars using period-end exchange rates. Revenues and expenses of foreign subsidiaries are translated at the average exchange rates in effect during the year. Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity. For the three months ended June 30, 2022 and 2021, we recorded net gains (losses) from currency translation adjustments of $(76.9) million and $14.3 million, respectively. For the six months ended June 30, 2022 and 2021, we recorded net losses from foreign currency translation of $(107.4) million and $(53.6) million, respectively. Gains and losses resulting from foreign currency transactions are reported in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.

We periodically enter into forward currency contracts in order to minimize the volatility that fluctuations in currency translation have on our monetary transactions. Under these arrangements, we typically agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates with maturities of less than twelve months, with some agreements extending to longer periods. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the unaudited condensed consolidated statements of income and comprehensive income.

As of June 30, 2022, we have several cross-currency and interest rate swap agreements with a notional value of $148.9 million of U.S. dollar to Swiss Franc and a notional value of $248.9 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. Under the GAAP hedge accounting guidance, changes in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in comprehensive income (loss) and remain in accumulated comprehensive income (loss) in shareholders’ equity until the sale or substantial liquidation of the foreign operation. For the three months ended June 30, 2022 and 2021, we recorded net gains from the changes in fair value of the derivatives of $18.0 million and net gains of $1.1 million, respectively. For the six months ended June 30, 2022 and 2021, we recorded net gains from the changes in fair value of the derivatives of $30.1 million and $28.8 million, respectively.

On December 7, 2021, we entered into a note purchase agreement, referred to as the 2021 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2021 Note Purchase Agreement, we issued and sold CHF 300 million aggregate principal amount of 0.88% series A senior notes and EUR 150 million aggregate principal amount of 1.03% series B senior notes due December 8, 2031. We designated our CHF 300 million series A senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. We designated our EUR 150 million series B senior notes as a hedge in our net investment in our Euro denominated net assets. Accordingly, the change in fair value of the 2021 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.

On December 11, 2019, we entered into a note purchase agreement, referred to as the 2019 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2019 Note Purchase Agreement, we issued and sold CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. We designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Accordingly, the change in fair value of the 2019 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.

For the three months ended June 30, 2022 and 2021, we recorded net gains (losses) from the changes in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $23.5 million and $(0.7) million, respectively. For the six months ended June 30, 2022 and 2021, we recorded net gains (losses) from the change in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $32.5 million and $20.0 million, respectively.

From time to time, we have entered into forward exchange contracts designed to minimize the volatility that fluctuations in foreign currency have on our cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, we agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates typically with maturities of less than twelve months with some agreements extending to longer periods. These transactions are recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. At June 30, 2022 and December 31, 2021, we had foreign exchange contracts with notional amounts aggregating $130.3 million and $180.7 million, respectively. We will continue to evaluate our currency risks and in the future may utilize foreign currency contracts more frequently.

### Interest Rate Risk

We regularly invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal because of our policy of investing in short-term financial instruments issued by highly rated financial institutions.

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. We currently have a higher level of fixed rate debt than variable rate debt, which limits the exposure to adverse movements in interest rates.

### Commodity Price Risk

We are exposed to certain commodity risks associated with prices for various raw materials. The prices of copper and certain other raw materials, particularly niobium-tin, used to manufacture superconductors, have increased significantly over the last decade. Copper and niobium-tin are the main components of low temperature superconductors and continued commodity price increases for copper and niobium, as well as other raw materials, may negatively affect our profitability. Periodically, we enter into commodity forward purchase contracts to minimize the volatility that fluctuations in the price of copper have on our sales of these products. At June 30, 2022 and December 31, 2021, we had fixed price commodity contracts with notional amounts aggregating $9.0 million and $5.5 million, respectively. The fair value of the fixed price commodity contracts at June 30, 2022 and December 31, 2021 was $(1.0) million and $0.4 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues. We will continue to evaluate our commodity risks and may utilize commodity forward purchase contracts more frequently in the future.

### Inflation Risk

We are subject to inflationary cost pressures across global supply chain networks. Certain components, parts, or materials are experiencing significant cost pressures that have impacted or may impact our cost of operations in future periods. Further, inflation has increased our general and administrative expenses and may vary between countries in which we operate. We continue to evaluate these cost increases in relation to our new orders and may continue to see a negative impact on our financial results for a period of time.

## Controls and procedures

As filed, 1,561 characters.

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2022. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2022.

Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly state, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

### Changes in Internal Controls over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 5, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-015090. Last ingested by Listed: Nov 5, 2026, 16:58 ET. No prices; not investment advice.
